Design Therapeutics (DSGN)
(Delayed Data from NSDQ)
$4.77 USD
+0.08 (1.71%)
Updated May 9, 2024 04:00 PM ET
After-Market: $4.76 -0.01 (-0.21%) 6:22 PM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
Balance Sheet
Fiscal Year End for Design Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 282 | 330 | 384 | 36 | -99,999 |
Receivables | 0 | 0 | 0 | 0 | NA |
Notes Receivable | 0 | 0 | 0 | 0 | NA |
Inventories | 0 | 0 | 0 | 0 | NA |
Other Current Assets | 3 | 5 | 1 | 0 | NA |
Total Current Assets | 285 | 335 | 385 | 36 | NA |
Net Property & Equipment | 2 | 2 | 2 | 0 | NA |
Investments & Advances | 0 | 0 | 0 | 0 | NA |
Other Non-Current Assets | 0 | 0 | 0 | 0 | NA |
Deferred Charges | 0 | 0 | 0 | 0 | NA |
Intangibles | 0 | 0 | 0 | 0 | NA |
Deposits & Other Assets | 0 | 0 | 0 | 0 | NA |
Total Assets | 290 | 341 | 391 | 37 | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | NA |
Accounts Payable | 2 | 3 | 2 | 1 | NA |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | NA |
Accrued Expenses | 8 | 8 | 4 | 1 | NA |
Income Taxes Payable | 0 | 0 | 0 | 0 | NA |
Other Current Liabilities | 0 | 0 | 0 | 0 | NA |
Total Current Liabilities | 10 | 11 | 5 | 2 | NA |
Mortgages | 0 | 0 | 0 | 0 | NA |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | NA |
Convertible Debt | 0 | 0 | 0 | 0 | NA |
Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | NA |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | NA |
Minority Interest (Liabilities) | 0 | 0 | 0 | 45 | NA |
Total Liabilities | 12 | 14 | 8 | 48 | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | NA |
Common Stock (Par) | 0 | 0 | 0 | 0 | NA |
Capital Surplus | 455 | 441 | 430 | 0 | NA |
Retained Earnings | -178 | -111 | -47 | -12 | NA |
Other Equity | 0 | -3 | 0 | 0 | NA |
Treasury Stock | 0 | 0 | 0 | 0 | NA |
Total Shareholder's Equity | 278 | 327 | 382 | -11 | NA |
Total Liabilities & Shareholder's Equity | 290 | 341 | 391 | 37 | NA |
Total Common Equity | 278 | 327 | 382 | -11 | 0 |
Shares Outstanding | 56.00 | 55.90 | 55.60 | NA | NA |
Book Value Per Share | 4.96 | 5.86 | 6.87 | 0.00 | 0.00 |
Fiscal Year End for Design Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 282 | 291 | 303 | 315 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 3 | 4 | 3 | 4 |
Total Current Assets | NA | 285 | 295 | 306 | 319 |
Net Property & Equipment | NA | 2 | 2 | 2 | 2 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 290 | 300 | 312 | 325 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 2 | 2 | 2 | 3 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 8 | 10 | 10 | 6 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 10 | 12 | 12 | 9 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 12 | 15 | 15 | 12 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 455 | 452 | 449 | 445 |
Retained Earnings | NA | -178 | -166 | -150 | -130 |
Other Equity | NA | 0 | -1 | -2 | -2 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 278 | 285 | 297 | 313 |
Total Liabilities & Shareholder's Equity | NA | 290 | 300 | 312 | 325 |
Total Common Equity | 0 | 278 | 285 | 297 | 313 |
Shares Outstanding | 56.40 | 56.00 | 55.90 | 55.90 | 55.90 |
Book Value Per Share | 0.00 | 4.96 | 5.10 | 5.31 | 5.60 |